Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORE phase 2 study of subretinal GT005 in geographic atrophy due to age-related macular degeneration
NL-OMON52776Phase 2Active, not recruiting
- Sponsor
- Gyroscope Therapeutics
- Start
- Jan 2020
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GT005 in age-related macular degeneration (AMD) (3 arms), sponsored by Gyroscope Therapeutics. Primary endpoint: Change in geographic atrophy area at Week 48. Started Jan 2020; status: active, not recruiting.
02
Drugs
GT005
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON52776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52776.